Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things - 2Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- 3RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- 4The Appearance of Experience: Embracing the Reduced Portage Horse
- 574 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
- The Latest: Fueling begins as NASA aims to send 1st crew to the moon in 53 years
- Astonishing interstellar comet captured in new images by NASA Mars missions
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- Tasting America: An Excursion Through Darling Cheap Food Brands
- How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- Jersey's wellbeing score is below UK and France
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- Monetary Strengthening: Assuming Command over Your Cash
- Artemis II live updates: NASA's historic moon mission set to make lunar flyby today
